FDA green lights Bizengri drug to treat rare, aggressive bile duct cancer
The U.S. Food and Drug Administration (FDA) has approved Bizengri to treat an ultra-rare, aggressive cancer that forms in the bile ducts.
May 11, 2026
0
2
Neoplasms: News and Research on Cholangiocarcinoma
MeSH tree: C04.557.470.200.025.450
New KIR-CAR T cell therapy shows promise in multiple solid cancers
An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma ...
Apr 20, 2026
0
6
Liver cancer roadmap links tumor hallmarks to treatment, including targetable mutations
A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide. ...
Apr 16, 2026
0
7
Radiation therapy improves outcomes for 'supermassive' bile duct tumors
A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors ...
Apr 2, 2026
0
1
Molecular test for bile duct cancer nearly doubles detection rate
When patients develop a narrowing or blockage in the bile ducts—the tubes connecting the liver, gallbladder and intestines—physicians must determine whether the cause is cancer or a benign condition. The location of these ...
Mar 27, 2026
0
6
Experts call to improve survival rates for bile duct cancer patients
The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid improvements in diagnosis, treatment and research for cholangiocarcinoma, also known as bile duct cancer. ...
Mar 2, 2026
0
31
Blocking CNNM4 protein with RNA technology could treat rare and aggressive liver cancer
An international study led by Dr. Malu Martínez-Chantar, principal investigator at CIC bioGUNE and CIBERehd, has identified a new therapeutic target for cholangiocarcinoma (CCA), a rare but highly aggressive liver cancer ...
Sep 17, 2025
0
15
Clinical trial leads to FDA approval of drug for rare, deadly blood cancer
Fewer than half of people diagnosed with a subtype of myeloid/lymphoid neoplasms are alive one year later. A multicenter Phase II trial, called FIGHT-203, led by Stanford Medicine, has led to FDA approval of a new drug treatment.
Aug 28, 2025
0
24
'Cell line atlas' provides a crucial resource for developing therapies for biliary tract cancer
Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. BTC is a rare and aggressive group of cancers, carrying one of the worst prognoses in all of oncology. Only ...
May 13, 2025
0
14
European study highlights inequalities in diagnosis and treatment of biliary tract cancer
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old now impacted by the disease. However, despite this, knowledge about these tumors remains low both ...
Feb 20, 2025
0
14
